Coivas review
Two prices are printed on the Coivas homepage and they are both true. The cards advertise semaglutide from $119 and tirzepatide from $199; the comparison block a scroll below gives $149 and $229, marked "after intro period". Most sellers publish only the first number and let you meet the second on a renewal invoice, so printing both is a point in its favor — and the second pair is what you should budget against. The medication is compounded only, held flat at every dose, and covers all 50 states. There is no Wegovy or Zepbound here, no oral option, and no mention of bloodwork anywhere on the site.
then $149/mo ongoing
- Independently scored
- Verified
Every medical claim in this piece is footnoted to the record it came from — the trial or the FDA label — so you can read the source rather than take the masthead's word for it. No one on this desk is your clinician.
Coivas at a glance
- Semaglutide
- $149/mo after the intro period
- Tirzepatide
- $229/mo after the intro period
- Coverage
- All 50 states
- Brand-name
- Compounded only
How we scored Coivas
Each score comes out of Coivas's published pricing, disclosures and oversight, and the six combine into the 61/100 Editors' Rating on the same weighted six-factor framework we apply to every provider — never nudged by whether a provider pays us.
The headline rate obscures a plan requirement or a hidden step-up.
Cost is unpredictable, premium, or hides behind a plan commitment.
Little here is shaped around a mother's week or her life stage.
Support is thin once the prescription ships.
Oversight and lab support fall short of the top of this roster — the review below says exactly where.
Cancellation is workable but not frictionless.
How we verified this review
- Last verified
- August 2026
- Confidence
- medium
- Primary source
- coivas.com
Checked against Coivas's own product cards and comparison chart in August 2026. It publishes both prices: $119 rising to $149 for semaglutide, $199 rising to $229 for tirzepatide, flat at every dose. The site adds that dosage and titration can change what you pay, so read those as starting points rather than firm quotes.
What to expect when you sign up
We walked Coivas's public signup funnel (August 2026) — a first-hand look at the flow. We don't create accounts, enter medical data, or complete checkout, so this is what any visitor sees, not a patient outcome.
- 1The signup call to action leaves coivas.com for intake.coivas.com, a separate host
- 2The intake responded HTTP 200 when checked on 2026-08-21
- 3Walked to the intake entry only. No personal information was submitted, so nothing past the entry screen is asserted here
What we noticed
- The intake runs on Bask Health rather than on the provider's own software
- No monthly price is visible on the public homepage; the number appears only after you begin the intake
- Intake is hosted on intake.coivas.com, so the company you fill the form in with is not the domain you started on
Pricing
Prices re-verified
| Medication | Monthly | Plan |
|---|---|---|
| Compounded semaglutide | $119 → $149 | All doses (flat)Advertised "From $119 · Monthly"; the comparison block gives $149 as the flat rate after the introductory period. |
| Compounded tirzepatide | $199 → $229 | All doses (flat)"From $199 · Monthly" to start, then $229, flat across the titration ladder. |
Swipe the table to see plan details →
GLP-1 telehealth is usually HSA- and FSA-eligible, so check your own plan. Everything above comes from Coivas's public disclosures at last review and change often; confirm the current number on Coivas's own site.
What we like
- Publishes the ongoing price beside the introductory one instead of burying it
- One flat rate at every dose, so titrating up does not raise the bill
- All 50 states, with consultation, prescription, medication, shipping and support inside the price
- Cancellable at any time, per its own subscription terms
The caveats
- The advertised $119 and $199 are introductory only — ongoing is $149 and $229
- Every figure carries a "from", and the site says dosage and titration can change what you pay
- Compounded only: no FDA-approved Wegovy, Ozempic, Zepbound or Mounjaro
- No oral or sublingual form
- Labs and bloodwork are not mentioned at all, so assume they are not included
- No postpartum, breastfeeding or PCOS guidance anywhere on the site
Coivas for mothers: our verdict
Two prices are printed on the Coivas homepage and they are both true. The cards advertise semaglutide from $119 and tirzepatide from $199; the comparison block a scroll below gives $149 and $229, marked "after intro period". Most sellers publish only the first number and let you meet the second on a renewal invoice, so printing both is a point in its favor — and the second pair is what you should budget against. The medication is compounded only, held flat at every dose, and covers all 50 states. There is no Wegovy or Zepbound here, no oral option, and no mention of bloodwork anywhere on the site. The advertised entry is $119, but the standing rate settles near $149/month — so read the headline as a starting offer, not the real monthly cost.
We weigh Coivas the way mothers actually have to: not just the real monthly cost, but the real monthly cost once the dose climbs and whether a real clinician stands behind it — the things a generic roundup never gets to.
What Coivas actually costs
- Compounded semaglutide — All doses (flat): $119 to start, then $149/mo
- Compounded tirzepatide — All doses (flat): $199 to start, then $229/mo
That sits below the roughly $179 median ongoing price across the providers we track for mothers — a real cost advantage.
The medications Coivas prescribes
Coivas prescribes semaglutide and tirzepatide — the pair with the strongest evidence behind them, and having both under one account matters when insulin resistance, familiar from PCOS and gestational diabetes, makes tirzepatide the better fit. These are compounded formulations from a licensed pharmacy — the reason the price stays down — but compounded GLP-1s aren't FDA-approved finished products the way Wegovy and Zepbound are.
Where Coivas fits — and where it doesn't — for mothers
Worth it if…
- the real monthly cost is a real barrier and you want a low, predictable number.
- you may need to move between semaglutide and tirzepatide as your body and hormones change.
- uninterrupted nationwide access matters — a move for family shouldn't interrupt care.
Give it a miss if…
- you specifically want an FDA-approved brand pen with its own pregnancy and lactation labeling.
- you'd rather a prescriber talk through timing around the real monthly cost once the dose climbs — that's what our #1 pick, CoreAge Rx, is built for.
Trust, safety, and oversight
Our confidence is moderate — the core facts check out, but some details (per-state availability, program mechanics) aren't fully public. As with any compounded GLP-1, the most useful thing mothers can do is confirm which licensed pharmacy fills the prescription and what's in the formulation — we explain how we weigh oversight in our Editors' Rating methodology.
One line that applies to every provider on this masthead: no GLP-1 is established as safe in pregnancy or while breastfeeding, and the labels advise against use. This is a review of a commercial program, not a green light — the timing decision belongs to you and your clinician.
The bottom line
Coivas is a genuine value play — weigh it on the real monthly cost once the dose climbs and whether a real clinician stands behind it against the alternatives below. For most mothers, CoreAge Rx remains the stronger all-round fit — see why it tops our ranking.
The bottom line for mothers
Best for: A mother comparing flat-rate compounded sellers who wants the post-introductory number in front of her before she starts, not after.
Alternatives to Coivas
Providers we have a referral relationship with, ordered by their Editors' Rating — highest first. A fee never moves a rating, but it does decide who appears here, so this is not the whole roster: the full ranking lists every provider we cover.
- Visit CoreAge RxCoreAge RxOur #1 pick
The one program on this masthead whose number still makes sense at the top of the dose. A flat, all-in monthly price on both molecules, no teaser rate to expire, and a cancel button you can actually find — the closest thing to a family-budget guarantee we've reviewed.
- Visit Gala Health
A flat $179 for either molecule and a genuinely gentle microdosing tier — a reasonable, all-doses-included option, if you can live with a yearly plan and a pharmacy the marketing never names.
- Visit Sesame
A high-trust telehealth marketplace that took a clear side: FDA-approved brand GLP-1 only, no compounded shortcut. You pay a brand cash price and book a real video visit — but you get on-label pens and one of the cleaner reputations on this masthead.
Keep comparing Coivas
Head-to-head & alternatives
Coivas, answered
- How much does Coivas cost?
- When we last checked, the cheapest ongoing compounded price at Coivas was around $149 a month: $149/mo after the intro period for semaglutide and $229/mo after the intro period for tirzepatide. Prices here move quickly — confirm today's all-in number on their own site before signing up.
- Is Coivas safe to use while breastfeeding?
- No GLP-1 has been shown to be safe in pregnancy or while nursing, whether compounded or brand-name, and the labeling advises against it. That applies to Coivas as much as to anyone else. Time it for after weaning, and make the decision with your own clinician.
- Does Coivas offer both semaglutide and tirzepatide?
- Yes — Coivas offers both molecules. Tirzepatide's dual GIP/GLP-1 action is often preferred where insulin resistance drives weight, which matters for PCOS and after gestational diabetes.
- Where does Coivas rank for mothers?
- Coivas takes 61/100 in our Editors' Rating, placing it #86. Six factors chosen for mothers feed that number, and CoreAge Rx is the one at the top of the list — see how they compare.
Pricing, states and verification reflect Coivas's public disclosures at last review; the Editors' Rating is our editorial judgment per the published methodology. This is background reading, not medical advice — GLP-1 medications are not established as safe in pregnancy or breastfeeding. See our medical disclaimer and how we're funded.